Beiträge

ampstream 2

Prof Devanshi Patel, Dr. med. Marc-Andrea Bärtsch

Ampstream

Prof Devanshi Patel

Hemato - Oncology

Univ.-Prof. Dr. med. Lars C. Hanker

Lungssss

DeLLphi-304 (SCLC): Tarlatamab verbessert intrakranielle Kontrolle

Prof. Dr. med. Ralf-Dieter Hofheinz, Univ.-Prof. Dr. med. Lars C. Hanker, Dr. med. Michael Pogorzelski

TRIPLEX (ES-SCLC): mehr Toxizität und kein Benefit durch thorakale Radiotherapie

Prof. Dr. med. Ralf-Dieter Hofheinz, Univ.-Prof. Dr. med. Lars C. Hanker, Dr. med. Michael Pogorzelski

CIRCULATE (CRC): ctDNA optimiert Therapieentscheidungen

Prof Devam1234 Shah, Prof. Dr. med. Ralf-Dieter Hofheinz, Univ.-Prof. Dr. med. Lars C. Hanker, Dr. med. Michael Pogorzelski

BREAKWATER und SWOG S2107 (BRAF-mCRC): Fortschritt in Erstlinie – Rückschlag in später Linie

Prof. Dr. med. Ralf-Dieter Hofheinz, Dr. med. Marc-Andrea Bärtsch, Univ.-Prof. Dr. med. Lars C. Hanker, Dr. med. Michael Pogorzelski

Phase II (LARC): Immun-Add-on verbessert Langzeitergebnisse

Prof. Dr. med. Ralf-Dieter Hofheinz, Univ.-Prof. Dr. med. Lars C. Hanker, Dr. med. Michael Pogorzelski

NRG-GY018 (EC): OS-Benefit durch Pembrolizumab

Prof. Dr. med. Ralf-Dieter Hofheinz, Univ.-Prof. Dr. med. Lars C. Hanker, Dr. med. Michael Pogorzelski